Blog

CRI congratulates SURGE Therapeutics on their completion of a $32 million Series B financing – Cancer Research Institute

Photo from businesswire.com

Jul 22, 2023, 19:34

CRI congratulates SURGE Therapeutics on their completion of a $32 million Series B financing – Cancer Research Institute

CRI congratulates SURGE Therapeutics, led by former CRI CLIP Award Grantee Michael Goldberg, Ph.D, on their completion of a $32 million Series B financing! This funding will be used to further develop the SURGE intraoperative immunotherapy approach, expand the team, and advance multiple clinical trials for its injectable biodegradable hydrogel, which may be administered during any surgical oncology procedure. SURGE Therapeutics recently dosed the first two patients in a Phase 1/2a trial for its lead intraoperative immunotherapy candidate, STM-416, in patients with recurrent bladder cancer, a major unmet medical need, to improve post-resection outcomes.

Read the full press release: Click here

Source: Cancer Research Institute/Linkedin

biodegradable hydrogel bladder cancer cancer Cancer Research Institute clinical trials immunotherapy Michael Goldberg OncoDaily Oncology SURGE Therapeutics

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Special Coverage